Capromorelin
Capromorelin is not a peptide. It is indexed alongside Growth hormone secretagogues because it appears in the same research literature and the same search demand; no statement on this site describes it as a peptide.
Identity
| Field | Value |
|---|---|
| Classification | Not a peptide |
| Primary class | Growth hormone secretagogues |
| CAS registry number | 193273-66-4[1] |
| PubChem CID | 216208[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C28H35N5O4[1] |
| Molecular weight | 505.6 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Capromorelin is not a peptide. A 2003 Bioorganic and Medicinal Chemistry paper reports its discovery among pyrazolinone-piperidine dipeptide growth hormone secretagogues, and a 2002 Bioorganic and Medicinal Chemistry Letters paper reports analogues with extended half-lives. A 2015 Spinal Cord paper reports pharmacokinetics in a single ascending dose phase I trial in spinal cord injury.
The bulk of the retrieved literature is veterinary. A 2018 Veterinary Medicine and Science review describes it as a ghrelin receptor agonist for stimulation of appetite in dogs, a 2016 Journal of Veterinary Internal Medicine paper reports a randomised placebo-controlled study in dogs with reduced appetite, 2017 papers in BMC Veterinary Research and the Journal of Veterinary Pharmacology and Therapeutics report food consumption and body weight endpoints in dogs, a 2018 paper reports daily administration in cats, and a 2021 Poultry Science paper reports feed intake in broiler chickens.
[3, 4, 5, 6, 7, 8, 9, 10, 11]Reported mechanism
A non-peptide ghrelin receptor agonist, described in the retrieved records as a growth hormone secretagogue acting at the ghrelin receptor.
[6, 3]Stated in the titles of the cited 2018 Veterinary Medicine and Science and 2003 Bioorganic and Medicinal Chemistry papers.
Targets named in the cited records: growth hormone secretagogue receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Capromorelin appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- CP-424391
- Entyce
Where this page sits
Research records
Cited research records for Capromorelin, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Ibutamoren — Growth hormone secretagogues
- Ghrelin — Growth hormone secretagogues
Named targets in the cited records
Class page: Growth hormone secretagogues. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Capromorelin?
Capromorelin is not a peptide. A 2003 Bioorganic and Medicinal Chemistry paper reports its discovery among pyrazolinone-piperidine dipeptide growth hormone secretagogues, and a 2002 Bioorganic and Medicinal Chemistry Letters paper reports analogues with extended half-lives.
Which class is Capromorelin indexed under?
Capromorelin is indexed under Growth hormone secretagogues. Growth hormone secretagogues are compounds that act at the growth hormone secretagogue receptor, the receptor for ghrelin, rather than at the growth hormone releasing hormone receptor.
What does the FDA application register show for Capromorelin?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 216208, Capromorelin. PubChem, National Library of Medicine (2026). pubchem:216208
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:capromorelin
- Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs). Discovery of capromorelin. Bioorganic & medicinal chemistry (2003). pmid:12538023
- Discovery and biological characterization of capromorelin analogues with extended half-lives. Bioorganic & medicinal chemistry letters (2002). pmid:12392732
- Pharmacokinetics of the ghrelin agonist capromorelin in a single ascending dose Phase-I safety trial in spinal cord-injured and able-bodied volunteers. Spinal cord (2015). pmid:25448190
- Capromorelin: a ghrelin receptor agonist and novel therapy for stimulation of appetite in dogs. Veterinary medicine and science (2018). pmid:29468076
- A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite. Journal of veterinary internal medicine (2016). pmid:27859746
- Capromorelin oral solution (ENTYCE®) increases food consumption and body weight when administered for 4 consecutive days to healthy adult Beagle dogs in a randomized, masked, placebo controlled study. BMC veterinary research (2017). pmid:28056951
- Capromorelin increases food consumption, body weight, growth hormone, and sustained insulin-like growth factor 1 concentrations when administered to healthy adult Beagle dogs. Journal of veterinary pharmacology and therapeutics (2017). pmid:27597271
- Evaluation of the safety of daily administration of capromorelin in cats. Journal of veterinary pharmacology and therapeutics (2018). pmid:29057482
- Capromorelin, a ghrelin receptor agonist, increases feed intake and body weight gain in broiler chickens (Gallus gallus domesticus). Poultry science (2021). pmid:34182219
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.